# Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma

> **NCT07715097** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Beijing Tricision Biotherapeutics Inc** · enrollment: 30 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Survivin-targeted DC Cell Injection

## Key facts

- **NCT ID:** NCT07715097
- **Lead sponsor:** Beijing Tricision Biotherapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07715097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07715097, "Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07715097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*